Skip to content

Kathryn A. Cunningham

8 papers in the library · 159 citations · publishing 1987-2025

Papers

Sort Most recent Most cited

The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.

Psychopharmacology August 1, 2025 Leah M Salinsky, Christina R Merritt, Erik J. Garcia et al. 8 citations

Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liability of cocaine is reliant upon inhibition of dopamine (DA) reuptake and consequent increase in DA efflux in meso-corticolimbic circuitry that controls reward and motivation. Cocaine also increases serotonin (5-HT) efflux which is integral in cocaine...

DOI: 10.1007/s00213-025-06765-3 (opens in new tab) Full text (opens in new tab) Serotonin −-2,5-dimethoxy-4-iodoamphetamine 5-ht2ar Behavioral economics +3

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.

Frontiers in Pharmacology 2023 Leah M Salinsky, Christina R Merritt, Joshua C Zamora et al. 14 citations

Opioid misuse and opioid-involved overdose deaths are a massive public health problem involving the intertwined misuse of prescription opioids for pain management with the emergence of extremely potent fentanyl derivatives, sold as standalone products or adulterants in counterfeit prescription opioids or heroin. The incidence of repeated opioid overdose events indicates a problematic use...

R‐(‐)2,5‐dimethoxy‐4‐iodoamphetamine (DOI) Blunts the Discriminative Stimulus Properties of Oxycodone

The FASEB Journal May 1, 2022 Leah M Salinsky, R. Fox, Noelle C Anastasio et al.

A record ~100,000 fatalities due to drug overdoses was reported in the U.S. for the twelve months preceding April 2021. Opioids account for most deaths, and recurrent opioid use may lead to the development of opioid use disorder (OUD), a debilitating chronic disorder. Current medication‐assisted OUD treatment (e.g., buprenorphine) mitigates withdrawal, reduces mortality, and reduces intake of...

Chapter 51. Hallucinogen-Related Disorders

American Psychiatric Publishing eBooks May 5, 2014 Robert N. Pechnick, Kathryn A. Cunningham, Itai Danovitch

The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well as thought, mood, and perceptual changes. Depending on dosage, expectation (set), and environment (setting), they also can induce euphoria and a state similar to a transcendental experience. These hallucinations can be present as part of a delirium...

The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain

Brain Research December 1, 2002 Paul S. Frankel, Kathryn A. Cunningham 41 citations

The hallucinogen d-lysergic acid diethylamide (d-LSD) evokes dramatic somatic and psychological effects. In order to analyze the neural activation induced by this unique psychoactive drug, we tested the hypothesis that expression of the immediate-early gene product c-Fos is induced in specific regions of the rat forebrain by a relatively low, behaviorally active, dose of d-LSD (0.16 mg/kg,...

Neuropharmacological reassessment of the discriminative stimulus properties ofd-lysergic acid diethylamide (LSD)

Psychopharmacology 1987 Kathryn A. Cunningham, J. B. Appel 84 citations

The neuropharmacological mechanisms underlying the behavioral effects of d-lysergic acid diethylamide (LSD) were assessed by comparing the discriminative stimulus properties of LSD with those of agonists and antagonists that act selectively at putative serotonin (5-hydroxytryptamine; 5-HT) receptor subtypes (5-HT1 and 5-HT2). Male Sprague-Dawley rats (N = 23) were trained to discriminate LSD...